IQVIA (NYSE:IQV) Insider Sells 4,446 Shares of Company Stock

Key Points

• IQVIA insider Eric Sherbet sold 4,446 shares at an average price of $278.83, totaling about $1.24 million. He retained 24,989 shares after the sale, a 15.1% reduction in his holdings.
• IQVIA shares fell 1.2% to $271.11 in Thursday trading. The company’s latest quarterly results beat estimates, with EPS of $3.34 and revenue of $4.43 billion, up 8% year over year.
• Analysts have a consensus “Moderate Buy” rating and an average price target of $294.21.

IQVIA Holdings Inc. (NYSE:IQV - Get Free Report) insider Eric Sherbet sold 4,446 shares of the company's stock in a transaction on Monday, November 9th. The stock was sold at an average price of $278.83, for a total value of $1,239,678.18. Following the transaction, the insider directly owned 24,989 shares in the company, valued at approximately $6,967,682.87. The trade was a 15.10% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link.

IQVIA Stock Down 1.2%

Shares of IQVIA stock traded down $3.42 during trading on Thursday, reaching $271.11. The company's stock had a trading volume of 1,041,118 shares, compared to its average volume of 1,427,896. The company has a quick ratio of 0.83, a current ratio of 0.83 and a debt-to-equity ratio of 2.18. The company has a market cap of $44.68 billion, a price-to-earnings ratio of 23.71, a P/E/G ratio of 2.44 and a beta of 1.16. IQVIA Holdings Inc. has a 1-year low of $154.50 and a 1-year high of $284.50. The company has a 50-day simple moving average of $267.67 and a two-hundred day simple moving average of $211.75.

IQVIA (NYSE:IQV - Get Free Report) last announced its earnings results on Tuesday, October 27th. The medical research company reported $3.34 earnings per share for the quarter, topping the consensus estimate of $3.26 by $0.08. IQVIA had a return on equity of 30.02% and a net margin of 8.05%. The firm had revenue of $4.43 billion for the quarter, compared to the consensus estimate of $4.37 billion. During the same period in the previous year, the business earned $3.00 EPS. The firm's revenue for the quarter was up 8.0% on a year-over-year basis. As a group, equities analysts forecast that IQVIA Holdings Inc. will post 11.53 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the stock. HSBC lifted their target price on shares of IQVIA from $280.00 to $300.00 and gave the stock a "buy" rating in a research note on Tuesday, September 1st. UBS Group started coverage on shares of IQVIA in a research note on Wednesday, September 30th. They set a "buy" rating and a $345.00 price target on the stock. Royal Bank Of Canada lifted their price objective on shares of IQVIA from $247.00 to $319.00 and gave the stock an "outperform" rating in a research note on Tuesday, September 29th. Jefferies Financial Group lifted their price objective on shares of IQVIA from $220.00 to $290.00 and gave the stock a "buy" rating in a research note on Wednesday, July 29th. Finally, Morgan Stanley boosted their price objective on shares of IQVIA from $240.00 to $270.00 and gave the company an "equal weight" rating in a report on Thursday, September 17th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $294.21.

Institutional Investors Weigh In On IQVIA

Large investors have recently bought and sold shares of the company. BlackRock Inc. purchased a new position in IQVIA during the 2nd quarter worth approximately $2,811,292,000. Dimensional Fund Advisors LP boosted its holdings in shares of IQVIA by 4.2% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,657,696 shares of the medical research company's stock valued at $282,657,000 after acquiring an additional 66,643 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of IQVIA by 9.0% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,634,264 shares of the medical research company's stock valued at $315,772,000 after acquiring an additional 134,997 shares during the last quarter. Canada Pension Plan Investment Board acquired a new stake in shares of IQVIA in the second quarter worth $240,911,000. Finally, Bank of America Corp DE acquired a new stake in shares of IQVIA in the second quarter worth $235,551,000. Hedge funds and other institutional investors own 89.62% of the company's stock.

IQVIA Company Profile

IQVIA Holdings Inc. provides clinical research services, healthcare data and analytics, and technology solutions to pharmaceutical, biotechnology, medical-device, and other healthcare organizations. Its services support the development and commercialization of medicines and other healthcare products. The company's offerings include clinical trial planning and management, real-world data and evidence, consulting, and software and technology platforms for life sciences research and commercial operations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.